Treatment

TAS3351 clinical trials

1 indexed studies · 0 currently recruiting

Ongoing, recruitingPhase I and Phase II (Integrated)- First administration to humans
A Phase 1/2 Study of TAS3351 in Patients with Advanced Non-Small Cell Lung Cancer and EGFR Mutations
This study is testing a new medicine called TAS3351 for people with a type of advanced lung cancer. It's for patients whose cancer has a specific change (EGFR mutation) that has become resistant to previous treatments. Researchers want to see if the medicine is safe and how well it works.
For: Patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) harboring an acquired C797S epidermal growth factor receptor (EGFR) mutation.
France · Netherlands · Germany